Covid-19: Patent, Economy, Prophylaxis and Treatment

Everyone around the globe is suffering from the Covid-19 pandemic and several industries are trying to overcome the economic turmoil.There is a steep decline in product sales & product manufacturing segments, Covid-19 and worldwide lockdowns has severely affected R&D activities as well.However, few industries like the mask, infrared based thermometer, PPE Kits, online meeting tools, media streaming, non-contact-based systems, pharmaceuticals, and few others have witnessed growth in licensing activity, sale of patented product &technology. Furthermore,such industries have even seen a significant growth in patent filing and patent prosecution related activities. Such observation has been recorded by Patent Prosecution experts working in these industry sectors. Currently, the disputes concerning patents are at an all-time low,however, Post the covid period surge in infringement and patent litigation activities is expected in the above mentioned industrial segments in the coming few months.

On the other hand, to curb the effect of Covid-19, academicians, universities, healthcare providers and companies across the globe are fueling their energies in search of a vaccine and drug candidate for prophylaxis and the treatment of COVID-19 disease. Several hundreds of clinical trials are underway to establish evidence around investigational drugs and to identify a suitable vaccine candidate. Currently, no pharmacologic therapies are available to treat COVID-19. A large number of clinical trials are ongoing to assess the suitability of several vaccine candidates such as synthetic chemical molecules, biological drugs, monoclonal antibodies, stem cells and plasma therapy etc. against the novel coronavirus treatment. In several cases, the old drugs are being repurposed to treat COVID19 patients. However, with no approved vaccine or treatment available for COVID-19, Moderna vaccine candidate and Gilead Sciences antiviral drug Remdesivir have shown a ray of hope. In this modern era of next generation technologies, we are able to develop multiple vaccine candidates in matter of few months, but the clinical efficacy, human safety testing and if approved, the mass production of vaccine are some of the hurdles which we need to tackle in order to develop a successful vaccine for the prophylaxic of COVID-19 pandemic.Our Pharmaceutical Research team at K&K has kept an eye on the developments related to Covid-19 vaccine and is continuously performing a detailed analysis of the ongoing clinical trials with respect to new drugs, treatment regimen and vaccine candidates pertaining to the Covid-19 pandemic. If you are interested in understanding the focus areas of the lead sponsors, herein below is the link to a recent report published by our Pharmaceutical Patent Research team, that gives an in-depth analysis of clinical trials, with relevant study-based material and treatment references. For ease of understanding, the report contains graphical representation of trends (study type, clinical trial stage, etc.) from the mined data of relevant clinical trials.

Click here to get a copy of the report and/or drop an email at sanjay@iiprd.com to receive updates on recent developments on Covid-19 vaccine directly from our Pharmaceutical Research team at K&K.

Leave a Reply

Your email address will not be published. Required fields are marked *

14 + five =

Archives

  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • July 2015
  • June 2015
  • May 2015
  • April 2015
  • March 2015
  • February 2015
  • January 2015
  • December 2014
  • November 2014
  • October 2014
  • September 2014
  • August 2014
  • July 2014
  • June 2014
  • May 2014
  • April 2014
  • March 2014
  • February 2014
  • January 2014
  • December 2013
  • November 2013
  • October 2013
  • September 2013
  • August 2013
  • July 2013
  • June 2013
  • May 2013
  • April 2013
  • March 2013
  • February 2013
  • January 2013
  • December 2012
  • November 2012
  • September 2012
  • August 2012
  • July 2012
  • June 2012
  • May 2012
  • April 2012
  • March 2012
  • February 2012
  • January 2012
  • December 2011
  • November 2011
  • October 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • April 2011
  • March 2011
  • February 2011
  • January 2011
  • December 2010
  • September 2010
  • July 2010
  • June 2010
  • May 2010
  • April 2010